SELLAS Life Sciences Group, Inc. — Investor Relations & Filings
Filings indexed
1,070
across all filing types
Latest filing
2026-05-12
Regulatory Filings
Country
US
United States of America
Listing
US
SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer) | 2026-05-12 | English | |
| 10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer) | 2026-05-12 | English | |
| SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject) | 2026-03-27 | English | |
| S-3ASR - SELLAS Life Sciences Group, Inc. (0001390478) (Filer) | 2026-03-20 | English | |
| SCHEDULE 13G/A Filing | 2026-01-30 | English | |
| 4 Filing | 2026-01-09 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 45339368 | 8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer) | 2026-05-12 | English | ||
| 45339290 | 10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer) | 2026-05-12 | English | ||
| 33063606 | SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject) | 2026-03-27 | English | ||
| 33002560 | S-3ASR - SELLAS Life Sciences Group, Inc. (0001390478) (Filer) | 2026-03-20 | English | ||
| 29310016 | SCHEDULE 13G/A Filing | 2026-01-30 | English | ||
| 29310101 | 4 Filing | 2026-01-09 | English | ||
| 29310097 | 4 Filing | 2026-01-09 | English | ||
| 29310058 | 4 Filing | 2026-01-09 | English | ||
| 29310033 | 4 Filing | 2026-01-09 | English | ||
| 29309973 | 4 Filing | 2026-01-09 | English | ||
| 29309972 | 4 Filing | 2026-01-09 | English | ||
| 29309957 | 4 Filing | 2026-01-09 | English | ||
| 29309997 | 8-K Filing | 2026-01-08 | English | ||
|
2025
2 filings
| |||||
| 12109617 | OWNERSHIP DOCUMENT | 2025-12-05 | English | ||
| 12109618 | OWNERSHIP DOCUMENT | 2025-12-05 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Adlai Nortye Ltd.
A clinical-stage biopharma firm developing cancer immunothe…
|
ANL | KY | Manufacturing |
|
ADLINE CHEM LAB LIMITED
Produces APIs, chemical intermediates, and specialty chemic…
|
524604 | IN | Manufacturing |
|
ADMA BIOLOGICS, INC.
Biopharmaceutical company that develops and manufactures pl…
|
ADMA | US | Manufacturing |
|
Advectus Life Sciences Inc.
Advances drug delivery systems using proprietary nanopartic…
|
AVXSF | CA | Manufacturing |
|
Adverum Biotechnologies, Inc.
A clinical-stage company developing gene therapies for ocul…
|
ADVM | US | Manufacturing |
|
Advicenne
A specialty pharmaceutical company developing treatments fo…
|
ALDVI | FR | Manufacturing |
|
AegirBio AB
A diagnostics company specializing in therapeutic drug moni…
|
AEGIR | SE | Manufacturing |
|
Aelis Farma
Biopharmaceutical company developing CB1 receptor inhibitor…
|
AELIS | FR | Manufacturing |
|
AEON Biopharma, Inc.
Clinical-stage company developing therapeutic applications …
|
AEON | US | Manufacturing |
|
Aequus Pharmaceuticals Inc.
Developing and commercializing specialty pharmaceutical pro…
|
AQS | CA | Manufacturing |
SELLAS Life Sciences Group, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33651/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33651 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33651 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33651 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33651}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SELLAS Life Sciences Group, Inc. (id: 33651)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.